U.S. Beverage Stock News

Church & Dwight is set to report its June 2026 quarter results on July 31, with analysts expecting earnings and revenue to be lower than a year earlier but still potentially ahead of consensus forecasts based on a positive Earnings ESP and recent estimate revisions. Analysts also highlight that Church & Dwight has exceeded consensus EPS estimates in each of the last four quarters, which is contributing to heightened investor attention around this upcoming announcement. With analysts flagging...

NovoCure recently reported its strongest-ever second quarter, with net revenue rising to US$183.58 million, a smaller net loss of US$15.66 million, and an upgraded 2026 net revenue outlook to US$710 million–US$725 million. The company also secured a CE Mark for its Optune Pax device in locally advanced pancreatic cancer and is anticipating FDA premarket approval for TTFields in brain metastases from non-small cell lung cancer, underscoring how expanding indications could reshape its...

Recently, brokers have upgraded their ratings on The Chemours Company, which now carries a Zacks Rank #1, backed by forecasts for stronger earnings growth into 2026. This shift in analyst sentiment highlights growing confidence in Chemours’ earnings outlook, potentially influencing how investors judge its longer-term profit recovery story. Next, we’ll examine how this uptick in broker ratings could reshape Chemours’ investment narrative around earnings quality and future growth. The latest...

Q2 Earnings Anticipation and Dividend Move Put Colgate-Palmolive in Focus Colgate-Palmolive (CL) is in the spotlight as investors look ahead to Q2 results, with attention on international performance, organic sales trends, and a higher quarterly dividend of US$0.53 per share. See our latest analysis for Colgate-Palmolive. At a share price of US$90.75, Colgate-Palmolive has had a mixed near term patch, with the share price return declining 2.4% over the past week but rising 7.8% over 90 days...

Tenet Healthcare (THC) is back on investors' radar after second quarter 2026 earnings and new full year guidance pointed to stronger profitability, higher revenue expectations and a larger share repurchase program. See our latest analysis for Tenet Healthcare. The latest earnings and guidance reset have clearly shifted sentiment, with Tenet Healthcare’s share price up 17.17% on the day and posting a 25.69% 3 month share price return. The 1 year total shareholder return of 52.40% and 3 year...

Edwards Lifesciences stock sits in an interesting spot for investors right now, with the Discounted Cash Flow (DCF) intrinsic value estimate suggesting the current price is roughly in line with fair value, while the broader valuation checks and recent 5 year share price record do not point to a clear bargain. Over the past 5 years, Edwards Lifesciences shares have declined 26.4%, which puts more focus on whether today’s price now fairly reflects the company’s prospects. Recent optimism...

TransUnion (TRU) has drawn fresh attention after introducing TruVision Alternative Credit Attributes (ACA 2.0) into its mortgage credit reports. The company is using FactorTrust data to broaden lender insight beyond traditional credit files and earlier in the loan funnel. See our latest analysis for TransUnion. Against this product update backdrop, TransUnion's share price has moved to $76.51, with a 30 day share price return of 8.76% and a 90 day gain of 7.47%. However, the 1 year total...

Why Charles Schwab Stock Is Back in Focus After Q2 Results Charles Schwab (SCHW) is drawing attention after reporting second quarter net income of US$2.8b and basic earnings per share of US$1.55, both higher than the figures reported a year earlier. See our latest analysis for Charles Schwab. Alongside the stronger Q2 and first half results and fresh dividend declarations, Charles Schwab’s share price has climbed to US$101.97, with a 30 day share price return of 12.46% and a 1 year total...

Earlier this month, Stoke Therapeutics appointed Thomas McCauley, Ph.D., as Chief Scientific Officer, adding more than 25 years of R&D and rare disease drug development leadership to its senior team. His background in advancing genetic and RNA-based medicines, including experience with mRNA technologies and antisense platforms, could be particularly relevant to Stoke’s antisense oligonucleotide programs targeting severe genetic diseases. Next, we’ll examine how bringing in a Chief Scientific...

Energy and commodity market infrastructure stocks are back in focus after fresh data on Intercontinental Exchange, or ICE, highlighted how quickly sentiment around trading venues and data providers can shift. Record open interest in ICE natural gas and power contracts has sharpened attention on where future cash flows might come from, while a P/E of 21.0x against a 16.8x fair value estimate and a share price about 6.3% above an intrinsic value estimate of US$137.18 underline valuation...

Citigroup stock has logged a very large 207.6% return over the past three years, yet current checks suggest it still trades at a discount, with both the Excess Returns intrinsic value estimate and earnings multiples pointing to an undervalued profile rather than a stretched one. Over the past three years, Citigroup has delivered a 207.6% return, which puts the current share price in focus against what the underlying value signals suggest. Recent progress on Citi's multi year transformation,...

Boyd Gaming reported past second-quarter 2026 results showing sales of US$733.7 million and revenue of US$1.03 billion, with net income easing to US$131.23 million and diluted EPS from continuing operations at US$1.75. Despite flat overall revenue and lower net income, Boyd Gaming highlighted growth in its Midwest and South operations, continued share repurchases and dividends above US$170 million, and raised guidance for its Online and Managed businesses. Now we’ll examine how Boyd Gaming’s...

In the second quarter of 2026, SEI Investments reported higher revenue of US$641.62 million but lower net income of US$195.66 million year-on-year, while also completing a US$6.13 billion share repurchase program first announced in 2005. SEI also expanded its product lineup by launching the SEI QiM U.S. Equity Factor Allocation Active ETF, giving investors access to its quantitative factor research through a transparent, tax-efficient vehicle. We’ll now examine how SEI’s strong revenue...

Investors in Financial Institutions, Inc. ( NASDAQ:FISI ) had a good week, as its shares rose 3.3% to close at US$40.62...

Colony Bankcorp, Inc. ( NYSE:CBAN ) investors will be delighted, with the company turning in some strong numbers with...

Quest Diagnostics Incorporated ( NYSE:DGX ) defied analyst predictions to release its second-quarter results, which...

It's been a good week for SouthState Bank Corporation ( NYSE:SSB ) shareholders, because the company has just released...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

The quarterly results for Tractor Supply Company ( NASDAQ:TSCO ) were released last week, making it a good time to...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see AptarGroup...

Intercontinental Exchange (ICE) has attracted fresh attention after releasing its June 2026 First Look on mortgage delinquency and foreclosure trends, highlighting sharply lower new FHA defaults and continued low early stage delinquencies. See our latest analysis for Intercontinental Exchange. Intercontinental Exchange shares have picked up momentum recently, with a 30 day share price return of 17.71% and a 7 day gain of 4.40%. This comes even though the year to date share price return is...

As you might know, Kaiser Aluminum Corporation ( NASDAQ:KALU ) just kicked off its latest second-quarter results with...

Aeva Technologies stock has delivered a very large 3 year gain, yet the current checks lean toward the shares trading at a premium rather than offering clear value today. Aeva Technologies is up 143.4% over 3 years, a result that puts long term holders in a strong position even though the share price has recently come under pressure. Future growth expectations for its sensing technology can support investor enthusiasm, but the path to consistent cash generation and funding its development...

Entegris stock has gained 44.2% year to date, yet the valuation checks lean expensive, raising the question of how much of the story is already reflected in the current price. Year to date, Entegris is up 44.2%, which means recent buyers are paying a substantially higher price than at the start of the year. Expectations for continued growth in Entegris' semiconductor materials business can support a premium, but any disappointment in execution or industry demand may weigh heavily on what...